Wegovy contains semaglutide, the same molecule as Ozempic. The difference is the licensed indication and, following from it, the dose. That difference is not a marketing detail when it comes to alcohol, and it is the most useful thing to understand about this drug. This article is part of our GLP-1 and Alcohol hub.
If you have read that Ozempic reduces alcohol cravings, everything in that research applies to the molecule in Wegovy. What changes is how much of it you are taking, and who is taking it.
# Same molecule, different licence
Semaglutide is sold under three names:
- Ozempic, weekly injection, licensed for type 2 diabetes
- Wegovy, weekly injection, licensed for weight management, titrated to a higher maintenance dose
- Rybelsus, daily tablet, licensed for type 2 diabetes, with much lower absorption
The active drug is identical. Wegovy simply climbs higher, because the weight-management licence supports a higher target dose than the diabetes one.
The clinical trial evidence on alcohol, covered in full in does Ozempic reduce alcohol cravings, is semaglutide evidence. It does not belong to one brand. The large electronic-health-record analyses and the small randomized trial published in JAMA Psychiatry in 2025 tell you about the molecule.
# Why the dose distinction matters here
Two reasons, and the second is the more interesting one.
The alcohol effect appears to strengthen with dose. This is the pattern across the animal work and the patient reports, and it is set out properly in GLP-1 doses and alcohol cravings. If that pattern holds, a Wegovy maintenance dose sits further along the curve than an Ozempic one. It is worth noting that the randomized trial detected an effect at relatively low doses, which suggests the low end is not nothing either.
Wegovy patients are, by definition, being treated for obesity. This matters more than it first appears, because the positive alcohol findings across this entire drug class cluster in people with obesity or diabetes. The one rigorous randomized trial of another drug in the class, exenatide in JCI Insight in 2022, found no overall effect on heavy drinking days but did find a reduction in the subgroup with obesity.
So the Wegovy population is arguably the population in which the alcohol signal has been most consistently observed. That is an argument from indirect evidence rather than a finding, but it is a reasonable one.
# What this does not license you to do
The obvious inference is that if higher doses do more, you should get to a higher dose. That inference has caused real harm and it needs stating clearly.
Titration exists for a reason. Semaglutide is stepped up over months specifically so the gut can adapt. Moving faster reliably produces severe nausea and vomiting, and sometimes worse.
You would be dosing for an unlicensed purpose. No regulator has approved semaglutide, under any brand, for alcohol use disorder. Wegovy is licensed for weight management, and a prescriber choosing your dose is choosing it for that.
Switching from Ozempic to Wegovy to chase an alcohol effect is not a decision the evidence supports. If you qualify for Wegovy on weight grounds, that is a conversation with your prescriber on its own merits.
Compounded semaglutide makes all of this worse. With a product of uncertain concentration you do not know your actual dose, which removes the one variable this whole article is about.
# Side effects at the higher dose
Gastrointestinal effects are dose-related, so the higher maintenance dose generally means more of them, particularly during titration steps.
For drinking specifically, this creates a confound worth understanding. If alcohol reliably makes you feel unwell on Wegovy, your intake may fall because of aversion rather than because your desire changed. Those are different things, they feel different, and only one of them is likely to survive a dose reduction. The distinction is covered in does Ozempic reduce alcohol cravings, and the practical side of drinking on any of these drugs is in can you drink alcohol on a GLP-1.
There is also a calorie angle that is more relevant on Wegovy than on Ozempic, because weight loss is the goal being measured. Alcohol delivers calories without fullness, and a few drinks can quietly consume a substantial part of a weekly deficit.
# Which research actually applies to you
A reasonable question if you are on Wegovy: when an article cites “the semaglutide study”, does it mean your dose or the diabetes dose?
Mostly the latter, and it is worth knowing.
The randomized trial published in JAMA Psychiatry in 2025 used relatively low doses of semaglutide, closer to the diabetes range than to Wegovy maintenance. The large electronic-health-record analyses drew heavily on populations prescribed semaglutide for diabetes, because that is who had been taking it longest by the time those records were analysed.
So the direct human evidence sits mostly below the dose you may be on. Two readings follow, and both are defensible. The optimistic one is that if an effect is detectable at lower doses, a higher dose plausibly does at least as much. The cautious one is that nothing has been measured at your dose, and pharmacology does not always scale the way intuition expects, as GLP-1 doses and alcohol cravings sets out.
What you should not conclude is that the research was done on people like you. On dose, it largely was not.
# What happens if you come off it
Worth planning for, because Wegovy is frequently interrupted by supply problems, cost, or a decision to stop after reaching a weight goal.
Nothing in the current evidence suggests these drugs produce a lasting change in drinking that persists once the medication stops. People who have come off report alcohol becoming interesting again over the following weeks, in the same way appetite returns.
The practical implication is that a stretch of drinking less on Wegovy is best treated as an opportunity rather than a cure. If your drinking has fallen, the useful work is building routines that do not depend on a weekly injection, so that the reduction has something holding it up if the injection stops.
# If you are on Wegovy and drinking less
This is a common and useful situation, and there are three things worth doing.
Record it rather than estimating it. Self-perception of drinking is unreliable in both directions, and a genuine reduction deserves better evidence than a feeling.
Note your titration dates. If the effect is dose-related, the weeks around each step up are where the change should appear. That pattern is invisible without dates.
Tell your prescriber. A drop in drinking is useful clinical information. If you were drinking heavily, a sharp reduction also has its own medical considerations and is not purely good news to be left unmentioned.
# How AlcoLog helps
Wegovy titration runs over months, which makes it precisely the case where memory fails and a log succeeds.
AlcoLog tracks medication doses, including GLP-1 agonists, alongside every logged drink, so a dose step and the weeks that follow it can be read together. One tap logs a drink. Weekly and monthly views turn a gradual change into a visible shape.
Because weight is often the reason for being on Wegovy in the first place, the alcohol-calorie side is tracked too, which makes visible the part of a deficit that drinking quietly consumes.
Medication is deliberately left out of the AlcoScore. Your dose log informs you and your prescriber rather than grading you. Everything stays on your device with no account or email, and export gives you something concrete for an appointment.
